Treatment of essential tremor with methazolamide.

We treated 28 patients (16 women and 12 men) who had essential tremor with methazolamide. Their median age was 69 years (range, 34 to 89 years), and the median duration of tremor was 16 years (range, less than 1 to 69 years). Fifteen cases were familial and 13 were sporadic. Improvement in 10 patients who continued taking the drug ranged from moderate to complete relief. In addition, four patients had marked improvement and two had moderate improvement but discontinued use of the drug because of side effects. Five patients with a mild response and seven with no response also discontinued methazolamide therapy. The maximal mean daily dose was 203 mg for all patients and 129 mg (maintenance dose) for the patients who continued taking the drug. Side effects consisted primarily of somnolence, nausea, epigastric discomfort, anorexia, paresthesias, and numbness. No aplastic anemia was noted in any of the patients. The median duration of follow-up was 6 months (range, 10 weeks to 29 months). The therapeutic effect seemed unrelated to a family history of tremor, the effect of alcohol, or the responsiveness to propranolol or primidone. Methazolamide may be an effective drug in the treatment of some patients with essential tremor, particularly those with head and voice tremor.

[1]  H. Teräväinen,et al.  Adrenergic beta2‐selective blocker in isoprenaline‐enhanced essential tremor , 1987, Movement disorders : official journal of the Movement Disorder Society.

[2]  W Koller,et al.  Kinetic predominant essential tremor , 1987, Neurology.

[3]  H. Krebs,et al.  Biochemical aspects of the transport of ions by nervous tissue. , 1952, The Biochemical journal.

[4]  M. Rubenstein,et al.  Acetazolamide-induced renal calculi. , 1975, The Journal of urology.

[5]  E. Block,et al.  Carbonic anhydrase inhibition in glaucoma: hazard or benefit for the chronic lunger? , 1978, Survey of ophthalmology.

[6]  L. Mogk,et al.  Blood dyscrasias and carbonic anhydrase inhibitors. , 1988, Ophthalmology.

[7]  B. Vogh,et al.  The effect of carbonic anhydrase inhibitors and other drugs on sodium entry to cerebrospinal fluid. , 1981, The Journal of pharmacology and experimental therapeutics.

[8]  J. T. Litchfield,et al.  The sulfonamides and allied compounds , 1948 .

[9]  S. H. Foster,et al.  Nonfatal Methazolamideinduced Aplastic Anemia , 1978 .

[10]  R. Liss,et al.  Blood dyscrasias in patients using methazolamide (neptazane) for glaucoma. , 1980, Ophthalmology.

[11]  B. Becker.  Use of methazolamide (neptazane) in the therapy of glaucoma; comparison with acetazolamide (diamox). , 1960, American journal of ophthalmology.

[12]  R Fava,et al.  Primidone in the long-term treatment of essential tremor: a prospective study with computerized quantitative analysis. , 1990, Clinical neuropharmacology.

[13]  Y. Ben-Arieh,et al.  Methazolamide-induced hepatitis and pure RBC aplasia. , 1981, Archives of internal medicine.

[14]  F. Roughton,et al.  Carbonic anhydrase. Its preparation and properties , 1933, The Journal of physiology.

[15]  F. Mcdowell.  The use of glutethimide for treatment of essential tremor , 1989, Movement disorders : official journal of the Movement Disorder Society.

[16]  W. Dawson,et al.  Electroretinal changes in the presence of a carbonic anhydrase inhibitor. , 1988, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

[17]  T. Maren,et al.  Sulphonamide carbonic anhydrase inhibitors and intra-ocular pressure in rabbits. A comparison between in vitro and in vivo activities based on tissue distributions and physical and chemical properties of nine compounds. , 2009, Acta pharmacologica et toxicologica.

[18]  T. Maren,et al.  Kinetic properties of primitive vertebrate carbonic anhydrases , 1980 .

[19]  W. Koller,et al.  Acute and chronic effects of propranolol and primidone in essential tremor , 1989, Neurology.

[20]  T. Maren.  The General Physiology of Reactions Catalyzed by Carbonic Anhydrase and Their Inhibition by Sulfonamides a , 1984, Annals of the New York Academy of Sciences.

[21]  A. J. Block,et al.  Acute respiratory failure precipitated by a carbonic anhydrase inhibitor. , 1976, Chest.

[22]  T. Maren,et al.  Sodium, chloride, and bicarbonate movement from plasma to cerebrospinal fluid in cats. , 1975, The American journal of physiology.

[23]  M. B. Shields,et al.  Urinary calculus during methazolamide therapy. , 1976, American journal of ophthalmology.

[24]  T. Maren,et al.  Carbonic anhydrase: chemistry, physiology, and inhibition. , 1967, Physiological reviews.

[25]  D. Campbell.  EFFECT OF NEPTAZANE ON INTRA-OCULAR PRESSURE IN RELATION TO ITS SYSTEMIC ACTION AND ITS CLINICAL APPLICATION*† , 1960, The British journal of ophthalmology.

[26]  G. Paulson,et al.  Efficacy of alprazolam for essential tremor , 1988, Neurology.

[27]  Robert C. Griggs,et al.  Hereditary paroxysmal ataxia , 1978, Neurology.

[28]  Wayne D. Gray,et al.  The anticonvulsant action of the carbonic anhydrase inhibitor methazolamide: possible involvement of a noradrenergic mechanism. , 1974, European journal of pharmacology.

[29]  T. Maren,et al.  Effects of carbonic anhydrase inhibition on cerebrospinal and intraocular fluids in the dog. , 2009, Acta pharmacologica et toxicologica.

[30]  R. Allen,et al.  Organic impotence associated with carbonic anhydrase inhibitor therapy for glaucoma. , 1987, Annals of ophthalmology.

[31]  R. Liss,et al.  Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma. , 1979, JAMA.

[32]  W. M. Wallace,et al.  Observations on the metabolic and clinical effects of carbonic-anhydrase inhibitors in epileptics. , 1952, A.M.A. American journal of diseases of children.

[33]  F. Roughton.  RECENT WORK ON CARBON DIOXIDE TRANSPORT BY THE BLOOD , 1935 .

[34]  B. Pakkenberg,et al.  Clozapine in the treatment of tremor , 1986, Acta neurologica Scandinavica.

[35]  C. A. Stone,et al.  The anticonvulsant effect of carbonic anhydrase inhibitors in mice--a noradrenergic mechanism of action. , 1973, European journal of pharmacology.

[36]  T. Maren,et al.  The pharmacology of methazolamide in relation to the treatment of glaucoma. , 1977, Investigative ophthalmology & visual science.

[37]  L. Findley.  The Pharmacological Management of Essential Tremor , 1986, Clinical neuropharmacology.

[38]  T. Maren,et al.  The carbon dioxide hydration activity of skeletal muscle carbonic anhydrase. Inhibition by sulfonamides and anions. , 1982, Molecular pharmacology.

[39]  W. Koller,et al.  Propranolol therapy for essential tremor of the head , 1984, Neurology.

[40]  D. Coop.  NEPTAZANE IN GLAUCOMA* , 1959, The British journal of ophthalmology.

[41]  S. Fahn.  Atypical tremors, rare tremors and unclassified tremors , 1984 .

[42]  R. Mayeux,et al.  Paroxysmal dystonic choreoathetosis in a patient with familial ataxia , 1982, Neurology.

[43]  J. Samples,et al.  Use of ophthalmic medications in pregnant and nursing women. , 1988, American journal of ophthalmology.

[44]  G. Gros,et al.  Inhibition properties and inhibition kinetics of an extracellular carbonic anhydrase in perfused skeletal muscle. , 1984, Respiration physiology.

[45]  W. Ashby,et al.  Relative distribution patterns of three brain enzymes, carbonic anhydrase, choline esterase and acetyl phosphatase. , 1952, The American journal of physiology.